Jin Zhou1, Lauren R Waskowicz2, Andrea Lim1, Xiao-Hui Liao3, Brian Lian4, Hiroko Masamune4, Samuel Refetoff3,5, Brian Tran4, Dwight D Koeberl2,6, Paul M Yen1,7,8. 1. 1Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, Singapore, Singapore. 2. 2Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina. 3. 3Department of Medicine, The University of Chicago, Chicago, Illinois. 4. 4Viking Therapeutics, San Diego, California. 5. 5Department of Pediatrics and Committee on Genetics, The University of Chicago, Chicago, Illinois. 6. 6Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina. 7. 7Department of Medicine, and Duke University Medical Center, Durham, North Carolina. 8. 8Department of Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.
Abstract
Background: Glycogen storage disease type Ia (GSD Ia), also known as von Gierke disease, is the most common glycogen storage disorder. It is caused by the deficiency of glucose-6-phosphatase, the enzyme that catalyzes the final step of gluconeogenesis and glycogenolysis. The accumulation of glucose-6-phosphate leads to increased glycogen and triglyceride levels in the liver. Patients with GSD Ia can develop steatohepatitis, cirrhosis, and increased risk for hepatocellular adenomas and carcinomas. We previously showed that animal models of GSD Ia had defective autophagy and dysfunctional mitochondria. In this study, we examined the effect of VK2809, a liver-specific thyroid hormone receptor β agonist, on hepatic steatosis, autophagy, and mitochondrial biogenesis in a mouse model of GSD Ia. Methods: G6pc-/--deficient (GSD Ia) mice were treated with VK2809 or vehicle control by daily intraperitoneal injection for four days. The hepatic triglyceride and glycogen were determined by biochemical assays. Autophagy and mitochondrial biogenesis were measured by Western blotting for key autophagy and mitochondrial markers. Results: VK2809 treatment decreased hepatic mass and triglyceride content in GSD Ia mice. VK2809 stimulated hepatic autophagic flux as evidenced by increased microtubule-associated protein light chain 3-II (LC3B-II), decreased p62 protein levels, activation of AMP-activated protein kinase (AMPK), inhibition of the mammalian target of rapamycin (mTOR) signaling, enhancement of protein levels of ATG5-ATG12, and increased lysosomal protein expression. VK2809 also increased the expression of carnitine palmitoyltransferase 1a (CPT1α) and fibroblast growth factor 21 (FGF21), as well as mitochondrial biogenesis to promote mitochondrial β-oxidation. Conclusions: In summary, VK2809 treatment decreased hepatic triglyceride levels in GSD Ia mice through its simultaneous restoration of autophagy, mitochondrial biogenesis, and β-oxidation of fatty acids. Liver-specific thyromimetics represent a potential therapy for hepatosteatosis in GSD Ia as well as nonalcoholic fatty liver disease.
Background: Glycogenstorage disease type Ia (GSD Ia), also known as von Gierke disease, is the most common glycogen storage disorder. It is caused by the deficiency of glucose-6-phosphatase, the enzyme that catalyzes the final step of gluconeogenesis and glycogenolysis. The accumulation of glucose-6-phosphate leads to increased glycogen and triglyceride levels in the liver. Patients with GSD Ia can develop steatohepatitis, cirrhosis, and increased risk for hepatocellular adenomas and carcinomas. We previously showed that animal models of GSD Ia had defective autophagy and dysfunctional mitochondria. In this study, we examined the effect of VK2809, a liver-specific thyroid hormone receptor β agonist, on hepatic steatosis, autophagy, and mitochondrial biogenesis in a mouse model of GSD Ia. Methods:G6pc-/--deficient (GSD Ia) mice were treated with VK2809 or vehicle control by daily intraperitoneal injection for four days. The hepatic triglyceride and glycogen were determined by biochemical assays. Autophagy and mitochondrial biogenesis were measured by Western blotting for key autophagy and mitochondrial markers. Results:VK2809 treatment decreased hepatic mass and triglyceride content in GSD Iamice. VK2809 stimulated hepatic autophagic flux as evidenced by increased microtubule-associated protein light chain 3-II (LC3B-II), decreased p62 protein levels, activation of AMP-activated protein kinase (AMPK), inhibition of the mammalian target of rapamycin (mTOR) signaling, enhancement of protein levels of ATG5-ATG12, and increased lysosomal protein expression. VK2809 also increased the expression of carnitine palmitoyltransferase 1a (CPT1α) and fibroblast growth factor 21 (FGF21), as well as mitochondrial biogenesis to promote mitochondrial β-oxidation. Conclusions: In summary, VK2809 treatment decreased hepatic triglyceride levels in GSD Iamice through its simultaneous restoration of autophagy, mitochondrial biogenesis, and β-oxidation of fatty acids. Liver-specific thyromimetics represent a potential therapy for hepatosteatosis in GSD Ia as well as nonalcoholic fatty liver disease.
Authors: D D Koeberl; B D Sun; T V Damodaran; T Brown; D S Millington; D K Benjamin; A Bird; A Schneider; S Hillman; M Jackson; R M Beaty; Y T Chen Journal: Gene Ther Date: 2006-05-04 Impact factor: 5.250
Authors: Edward E Cable; Patricia D Finn; Jeffrey W Stebbins; Jinzhao Hou; Bruce R Ito; Paul D van Poelje; David L Linemeyer; Mark D Erion Journal: Hepatology Date: 2009-02 Impact factor: 17.425
Authors: Mark D Erion; Edward E Cable; Bruce R Ito; Hongjian Jiang; James M Fujitaki; Patricia D Finn; Bao-Hong Zhang; Jinzhao Hou; Serge H Boyer; Paul D van Poelje; David L Linemeyer Journal: Proc Natl Acad Sci U S A Date: 2007-09-18 Impact factor: 11.205
Authors: James M Fujitaki; Edward E Cable; Bruce R Ito; Bao-Hong Zhang; Jinzhao Hou; Chun Yang; David A Bullough; James L Ferrero; Paul D van Poelje; David L Linemeyer; Mark D Erion Journal: Drug Metab Dispos Date: 2008-08-14 Impact factor: 3.922
Authors: Robert H J Bandsma; Berthil H Prinsen; Monique de Sain van Der Velden; Jan-Peter Rake; Theo Boer; G Peter A Smit; Dirk-Jan Reijngoud; Folkert Kuipers Journal: Pediatr Res Date: 2008-06 Impact factor: 3.756
Authors: Nicolas Ochs; Reto Auer; Douglas C Bauer; David Nanchen; Jacobijn Gussekloo; Jacques Cornuz; Nicolas Rodondi Journal: Ann Intern Med Date: 2008-05-19 Impact factor: 25.391
Authors: Andrea Perra; Gabriella Simbula; Michela Simbula; Monica Pibiri; Marta A Kowalik; Pia Sulas; Maria T Cocco; Giovanna M Ledda-Columbano; Amedeo Columbano Journal: FASEB J Date: 2008-04-23 Impact factor: 5.191
Authors: Michael K Badman; Pavlos Pissios; Adam R Kennedy; George Koukos; Jeffrey S Flier; Eleftheria Maratos-Flier Journal: Cell Metab Date: 2007-06 Impact factor: 27.287
Authors: Zollie A Yavarow; Hye-Ri Kang; Lauren R Waskowicz; Boon-Huat Bay; Sarah P Young; Paul M Yen; Dwight D Koeberl Journal: Hum Mol Genet Date: 2020-01-15 Impact factor: 6.150
Authors: Jin Zhou; Brijesh K Singh; Jia Pei Ho; Andrea Lim; Eveline Bruinstroop; Kenji Ohba; Rohit A Sinha; Paul M Yen Journal: Autophagy Date: 2021-03-18 Impact factor: 16.016
Authors: Jin Zhou; Karine Gauthier; Jia Pei Ho; Andrea Lim; Xu-Guang Zhu; Cho Rong Han; Rohit Anthony Sinha; Sheue-Yann Cheng; Paul Michael Yen Journal: Endocrinology Date: 2021-08-01 Impact factor: 5.051